|Closed||Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD)
The purpose of this study is to look at the effects, good or bad, of an experimental combination of low-dose total body irradiation (TBI) and chemotherapy drugs, given prior to stem-cell transplantation, in patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
The chemotherapy drugs used in this research study are treosulfan and fludarabine. These drugs will be given along with low-dose total body irradiation (TBI). Study participants will then undergo a donor bone-marrow or peripheral-blood stem-cell transplant.
Participants will receive treatment at the Seattle Cancer Care Alliance (SCCA) and at the University of Washington Medical Center (UWMC).
Treatment on this study will last about 3 ½ months. We would like to do long-term follow-up by calling each study participant on the telephone once a year to see how he or she is doing.
1. Age 60 years or younger
2. Diagnosed with one of the following:
- Acute myeloid leukemia (AML) beyond 1st remission, or intermediate or high-risk AML in 1st complete remission
- Myelodysplastic syndrome (MDS)
3. A suitable donor is available
Other eligibility criteria may apply.
Prior or concurrent umbilical cord blood transplantation (prior autologous or allogeneic hematopoietic stem cell transplantation is allowed)
Inadequate organ function (heart, lung, kidney, liver)
Active infectious disease, HIV-positivity, or active infectious hepatitis
CNS leukemic involvement
Pregnant or lactating Other exclusion criteria may apply.
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.